AGREEMENTLicense Agreement • December 3rd, 2013 • Santarus Inc • Pharmaceutical preparations
ContractMerger Agreement • December 3rd, 2013 • Santarus Inc • Pharmaceutical preparations
We are pleased to inform you that, on November 7, 2013, Santarus, Inc. (“Santarus”) entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with Salix Pharmaceuticals, Ltd. (“Parent”), Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Parent, and Willow Acquisition Sub Corporation, a wholly owned indirect subsidiary of Parent (“Purchaser”). In accordance with the Merger Agreement, Purchaser has today commenced a tender offer (the “Offer”) to purchase all of the outstanding shares of our common stock, par value $0.0001 per share (the “Shares”), at a price per Share of $32.00, net to the holder thereof in cash, without interest (the “Offer Price”) and subject to any withholding of taxes required by applicable law.
